Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm, Abscopal Responses Achieved in Prostate Cancer

Noxopharm (ASX:NOX) today releases details of the radiographic review of its DARRT-1 clinical study and is pleased to report that it shows a major benefit from a combination of Veyonda® and low-dose radiotherapy.

For further information, please download the attached PDF. 
Download this document